Regional variations in fluoroquinolone non-susceptibility among Escherichia coli bloodstream infections within the Veterans Healthcare Administration

Antimicrobial Resistance and Infection Control

Volumn 5, Issue 1, 2016, Pages

  Livorsi, Daniel J ^a,b   Goto, Michihiko ^a,b   Carrel, Margaret ^c   Jones, Makoto M ^d,e   McDanel, Jennifer ^a,f   Nair, Rajeshwari ^a,b   Alexander, Bruce ^a   Beck, Brice ^a   Richardson, Kelly K ^a   Perencevich, Eli N ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c University of Iowa   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF IOWA   (United States)

Author keywords

Antimicrobial resistance; Epidemiology; Escherichia coli; Fluoroquinolones

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN;

ARTICLE; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BLOOD CULTURE; BLOODSTREAM INFECTION; COHORT ANALYSIS; COMMUNITY ACQUIRED INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FLUOROQUINOLONE NON SUSCEPTIBILITY; GEOGRAPHICAL VARIATION (SPECIES); HEALTHCARE ASSOCIATED INFECTION; HUMAN; NONHUMAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREND STUDY; UNITED STATES;

EID: 84992152295     PISSN: None     EISSN: 20472994     Source Type: Journal    
DOI: 10.1186/s13756-016-0135-2     Document Type: Article

References (27)

1. Fasugba O, Gardner A, Mitchell BG, Mnatzaganian G. Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies. BMC Infect Dis. 2015;15:545.
2. Zervos MJ, Hershberger E, Nicolau DP, Ritchie DJ, Blackner LK, Coyle EA, Donnelly AJ, Eckel SF, Eng RH, Hiltz A, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis. 2003;37(12):1643-8.
3. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother. 2012;56(4):2181-3.
4. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133-64.
5. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-20.
6. CLSI. Analysis and presentation of cumulative antimicrobial susceptibility test data. Wayne: Clinical and Laboratory Standards Institute; 2014.
7. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137(10):791-7.
8. Banerjee R, Johnson JR. A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131. Antimicrob Agents Chemother. 2014;58(9):4997-5004.
9. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother. 2011;66(1):1-14.
10. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. ClinInfect Dis. 2010;51(3):286-94.
11. Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents. 2010;35(4):316-21.
12. Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, Kuskowski MA, Tchesnokova V, Sokurenko EV, Johnson JR, et al. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis. 2013;57(9):1256-65.
13. Banerjee R, Johnston B, Lohse C, Porter SB, Clabots C, Johnson JR. Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol. 2013;34(4):361-9.
14. Croxall G, Hale J, Weston V, Manning G, Cheetham P, Achtman M, McNally A. Molecular epidemiology of extraintestinal pathogenic Escherichia coli isolates from a regional cohort of elderly patients highlights the prevalence of ST131 strains with increased antimicrobial resistance in both community and hospital care settings. J Antimicrob Chemother. 2011;66(11):2501-8.
15. Johnson JR, Tchesnokova V, Johnston B, Clabots C, Roberts PL, Billig M, Riddell K, Rogers P, Qin X, Butler-Wu S, et al. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis. 2013;207(6):919-28.
16. Maslow JN, Lee B, Lautenbach E. Fluoroquinolone-resistant Escherichia coli carriage in long-term care facility. Emerg Infect Dis. 2005;11(6):889-94.
17. Burgess MJ, Johnson JR, Porter SB, Johnston B, Clabots C, Lahr BD, Uhl JR, Banerjee R. Long-Term Care Facilities Are Reservoirs for Antimicrobial-Resistant Sequence Type 131 Escherichia coli. Open Forum Infectious Diseases. 2015;2(1):ofv011.
18. Han JH, Johnston B, Nachamkin I, Tolomeo P, Bilker WB, Mao X, Clabots C, Lautenbach E, Johnson JR, Program CDCPE. Clinical and molecular epidemiology of Escherichia coli sequence type 131 among hospitalized patients colonized intestinally with fluoroquinolone-resistant E. coli. Antimicrob Agents Chemother. 2014;58(11):7003-6.
19. Mohamed M, Clabots C, Porter SB, Thuras P, Johnson JR. Isolation and Characterization of Escherichia coli Sequence Type 131 and Other Antimicrobial-Resistant Gram-Negative Bacilli from Clinical Stool Samples from Veterans. Antimicrob Agents Chemother. 2016;60(8):4638-45.
20. Loeb MB, Craven S, McGeer AJ, Simor AE, Bradley SF, Low DE, Armstrong-Evans M, Moss LA, Walter SD. Risk factors for resistance to antimicrobial agents among nursing home residents. Am J Epidemiol. 2003;157(1):40-7.
21. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis. 1995;20(3):557-60.
22. Liss MA, Johnson JR, Porter SB, Johnston B, Clabots C, Gillis K, Nseyo U, Holden M, Sakamoto K, Fierer J. Clinical and microbiological determinants of infection after transrectal prostate biopsy. Clin Infect Dis. 2015;60(7):979-87.
23. Johnson JR, Polgreen PM, Beekmann SE. Transrectal prostate biopsy-associated prophylaxis and infectious complications: report of a query to the emerging infections network of the infectious diseases society of America. Open Forum Infectious Diseases. 2015;2(1):ofv002.
24. Peralta G, Sanchez MB, Garrido JC, De Benito I, Cano ME, Martinez-Martinez L, Roiz MP. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother. 2007;60(4):855-63.
25. Kuikka A, Sivonen A, Emelianova A, Valtonen VV. Prognostic factors associated with improved outcome of Escherichia coli bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis. 1997;16(2):125-34.
26. Thom KA, Schweizer ML, Osih RB, McGregor JC, Furuno JP, Perencevich EN, Harris AD. Impact of empiric antimicrobial therapy on outcomes in patients with Escherichia coli and Klebsiella pneumoniae bacteremia: a cohort study. BMC Infect Dis. 2008;8:116.
27. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother. 2004;48(12):4574-81.